SCHEMBL4683467

SCHEMBL4683467

Cc1ccc(C(=O)NC(NC(=S)Nc2cccc(C)c2)C(F)(F)F)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.55
MAPT P10636 11/20 0.55
NPSR1 Q6W5P4 3/20 0.55
SMN1; SMN2 Q16637 6/20 0.52
RAB9A P51151 6/20 0.52
NPC1 O15118 5/20 0.52
MEN1 O00255 8/20 0.51
KMT2A Q03164 8/20 0.51
LMNA P02545 8/20 0.51
ALOX12 P18054 5/20 0.50
HPGD P15428 2/20 0.50
HTT P42858 5/20 0.48
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP2D6 P10635 1/20 0.47
STAT1 P42224 1/20 0.46
TP53 P04637 1/20 0.46
NFKB1 P19838 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4683858 0.91 ALDH1A1 (0.50) ALDH1A1MAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL4682172 0.89 MAPT (0.56) ALDH1A1MAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL5218080 0.88 ALDH1A1 (0.61) ALDH1A1MAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL4684022 0.88 KMT2A (0.63) ALDH1A1MAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL4683927 0.86 HSP90AA1 (0.59) ALDH1A1MAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL4738582 0.83 MEN1 (0.58) ALDH1A1MAPTNPSR1RAB9ANPC1
SCHEMBL6649296 0.83 MEN1 (0.58) ALDH1A1MAPTNPSR1RAB9ANPC1
SCHEMBL4682689 0.83 ABCC9 (0.67) ALDH1A1MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL4679775 0.82 LMNA (0.53) ALDH1A1MAPTNPSR1SMN1; SMN2MEN1
SCHEMBL6672512 0.82 LMNA (0.53) ALDH1A1MAPTNPSR1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1198456-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2007-09-19 EP claimed
EP-1392655-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2004-03-03 EP claimed
JP-2003506355-A 2003-02-18 JP claimed
WO-2002062762-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO claimed
EP-1198456-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2002-04-24 EP claimed
US-20020028836-A1 Potassium channel openers ABBVIE INC. 2002-03-07 US claimed
WO-2001009096-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2001-02-08 WO claimed
EP-1392655-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2008-07-16 EP disclosed
EP-1198456-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2007-09-19 EP disclosed
EP-1392655-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2004-03-03 EP disclosed
US-6645968-B2 E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; ABBOTT LABORATORIES 2003-11-11 US disclosed
WO-2002062762-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO disclosed
EP-1198456-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2002-04-24 EP disclosed
US-20020028836-A1 Potassium channel openers ABBVIE INC. 2002-03-07 US disclosed
WO-2001009096-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2001-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028836-A1 Potassium channel openers KCNJ2, KCNJ11, KCNJ1 ALDH1A1 704/4885MAPT 2939/4885NPSR1 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.